Pharmaceuticals Sector - Solvay

More documents

Recommendations

Info

94 Solvay Global Annual Report 2005 Solvay Elektrolysespezialitaeten GmbH Ch absorbed by Solvay Chemicals GmbH Solvay Fluor GmbH Ch absorbed by Solvay Fluor GmbH BP Solvay Polyéthylène (Deutschland) GmbH Pl sold SPAIN BP Solvay Polyéthylène Ibérica S.L. Pl sold GREAT BRITAIN Solvay Finance (Jersey) Ltd - liquidated BP Solvay Polyéthylène (UK) GCAS Pl sold Solvay Polyolefi ns (UK) Ltd Pl sold CHINA Chuanlu Plastic Sales & Services Co. Ltd Pl sold UNITED STATES BP Solvay Olefi ns, LP Pl sold BP Solvay Polyéthylène North America Pl sold BRAZIL Solvay Polietileno Ltda Pl deconsolidated Change in consolidation method Country Company Sector Comments GERMANY Solvay & CPC Barium Strontium GmbH & Co KG Ch Barium JV 75% MEXICO Solvay & CPC Barium Strontium Monterrey S. de R.L. de C.V. Ch Barium JV 75%
List of fully consolidated Group companies indicating the percentage holding, followed by the Sector It should be noted that the percentage of voting rights is very close to the percentage holding. Ch = Chemicals Ph = Pharmaceuticals Pl = Plastics - = not allocated BELGIUM Alkor Draka S.A., Oudenaarde 100 Pl Financière Keyenveld S.A., Bruxelles 100 - Fournier Pharma S.A., Bruxelles 100 Ph Mutuelle Solvay S.C.S., Bruxelles 99.9 - Peptisyntha S.A., Neder-Over-Heembeek 100 Ph Solvay Benvic & Cie Belgium S.N.C., Bruxelles 100 Pl Solvay Chemicals International S.A., Bruxelles 100 Ch Solvay Chemie S.A., Bruxelles 100 Ch Solvay Coordination Internationale des Crédits Commerciaux (CICC) S.A., Bruxelles 100 - Solvay Industrial Foils Management and Research S.A.- SIFMAR, Bruxelles 100 Pl Solvay Participations Belgique S.A., Bruxelles 100 - Solvay Pharma & Cie S.N.C., Bruxelles 100 Ph Solvay Pharmaceuticals S.A.- Management Services, Bruxelles LUXEMBOURG 100 Ph Solvay Pharmaceuticals S.a.r.l., Luxembourg NETHERLANDS 100 Ph Physica B.V., Weesp 100 Ph Sodufa B.V., Weesp 100 Ph Solvay Chemie B.V., Linne-Herten 100 Ch Solvay Draka B.V., Enkhuizen 100 Pl Solvay Finance B.V., Weesp 100 - Solvay Holding Nederland B.V., Weesp 100 - Solvay Pharma B.V., Weesp 100 Ph Solvay Pharmaceuticals B.V., Weesp FRANCE 100 Ph Alkor Draka S.A.S., Roissypole Le Dôme 100 Pl BTG Pharma S.A.S., Paris 100 Ph Fournier Industrie et Santé S.A., Chenove 100 Ph Laboratoires Fournier S.A., Chenove 100 Ph Ondex S.A.S., Chevigny-St-Sauveur 100 Pl Synkem S.A.S., Chenove 100 Ph Solvay Benvic France S.A.S., Paris 100 Pl Solvay - Carbonate - France S.A.S., Paris 100 Ch Solvay - Electrolyse - France S.A.S., Paris 100 Ch Solvay Finance France S.A., Paris 100 - Solvay - Fluorés - France S.A.S., Paris 100 Ch Solvay - Olefi nes - France S.A.S., Paris 100 Pl Solvay Global Annual Report 2005 95
Page 1 and 2:
Driven by the future Growth, Compet
Page 3 and 4:
Highlights January 2005 Solvay fi n
Page 5 and 6:
Activities Group sales 2005 = EUR 8
Page 7 and 8:
Our Vision - Independent industrial
Page 9 and 10:
here to stay, in our view irreversi
Page 11 and 12:
Board of Directors and Corporate Go
Page 13 and 14:
4 Executive Committee and General M
Page 15 and 16:
Such a strategy is possible only wi
Page 17 and 18:
Specialities Solvay Specialties fro
Page 19 and 20:
Key fi gures [EUR million] Pharmace
Page 21 and 22:
Cardiometabolic Cardiovascular dise
Page 23 and 24:
Cardiometabolics Fenofi brate, TRIC
Page 25 and 26:
“ DUODOPA® entered Solvay’s pr
Page 27 and 28:
Pharmaceuticals Sector Therapeutic
Page 29 and 30:
Key fi gures [EUR million] Chemical
Page 31 and 32:
Growth To speed up its growth, the
Page 33 and 34:
Initiatives have also been launched
Page 35 and 36:
“ The ‘Soil Remediation Reagent
Page 37 and 38:
Key fi gures [EUR million] Plastics
Page 39 and 40:
Innovation “Twin-Sheet Blow Mould
Page 41 and 42:
Plastics 37 Solvay Global Annual Re
Page 43 and 44:
which it was able to take advantage
Page 45 and 46:
New Business Development Priority t
Page 47 and 48: Meeting The Science Days organized
Page 49 and 50: Human Resources The Group’s fi ve
Page 51 and 52: “ At the end of this seminar, all
Page 53 and 54: Sustainable Development 2005 saw th
Page 55 and 56: Accident frequency rate Persons wor
Page 57 and 58: Management Report New records for S
Page 59 and 60: Expenditure on the future by Sector
Page 61 and 62: Financial Statements The following
Page 63 and 64: Consolidated balance sheet EUR mill
Page 65 and 66: IFRS valuation rules The main accou
Page 67 and 68: 9. Impairment Every year the Group
Page 69 and 70: Notes to the fi nancial statements
Page 71 and 72: (2) Financial data by region These
Page 73 and 74: and the estimated fi nancial conseq
Page 75 and 76: The deferred taxes recorded in the
Page 77 and 78: 2005 Millions EUR Acquisitions Disp
Page 79 and 80: Neopharma On January 19, 2005 the S
Page 81 and 82: (around 300 persons) with a view to
Page 83 and 84: In 2005 the impairment tests on goo
Page 85 and 86: Solvay Group purchased 100% of the
Page 87 and 88: Post-employment benefi t plans are
Page 89 and 90: Actuarial assumptions used in deter
Page 91 and 92: Analysis of total fi nancial debt b
Page 93 and 94: In this way, at the end of 2005, th
Page 95 and 96: The following amounts relating to J
Page 97: PORTUGAL Fournier Farmaceutica Port
Page 101 and 102: Solvay Salz Holding GmbH, Hannover
Page 103 and 104: CANADA Fournier Pharma, Inc., Montr
Page 105 and 106: GREAT BRITAIN Inergy Automotive Sys
Page 107 and 108: Summary fi nancial statements of So
Page 109 and 110: Statutory auditor’s report to the
Page 111 and 112: The Solvay share compared with the
Page 113 and 114: Contacts: The Investor Relations Te
Page 115 and 116: Shareholders’ Diary - May 9, 2006
show all

Pharmaceuticals Sector - Solvay

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?